Hot Products

Cucurbitacin I
Catalog No: CFN70316

Cucurbitacin I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells. Cucurbitacin I elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-kinase, it promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma. Cucurbitacin I may inhibit P-gp-mediated transport and interact with P-gp substrates in the intestinal absorption process.

Cucurbitacin IIA
Catalog No: CFN98171

Cucurbitacin IIa has anti-cancer, anti-bacterial, and anti-inflammatory effects, it can induce apoptosis and enhance autophagy; it also can disrupt the actin cytoskeleton and direct the cell to undergo PARP-mediated apoptosis through the inhibition of survivin downstream of JAK2/STAT3.

Cucurbitacin IIb
Catalog No: CFN90376

Cucurbitacin IIb is one of the major active compounds in Hemsleyadine tablets which have been used for clinical treatment of bacillary dysentery, enteritis and acute tonsilitis. Cucurbitacin IIb exhibits its anti-inflammatory activity through modulating multiple cellular behaviors and signaling pathways, leading to the suppression of the adaptive immune response. Cucurbitacin IIb also can induce apoptosis of concanavalin A-activated mouse lymphocytes.

Cucurbitacin Q1
Catalog No: CFN91760

Cucurbitacin R
Catalog No: CFN92895

Cucurbitacin R, a natural anti-inflammatory product, has been shown to exhibit activity against both adjuvant-induced arthritis and delayed-type hypersensitivity reactions induced by various agents; it has the potential to be a new immunosuppressive agent with antiproliferative effects through the inhibition of the NFAT with anti-inflammatory activity in DTH reactions. Cucurbitacin R can exert antitumorigenic activity in the absence of activated STAT3.

Cucurbitacin S
Catalog No: CFN90535

Cucurbitacins from Wilbrandia ebracteata have analgesic effects. Cucurbitacin S has anticancer and antiinflammatory activities.

Cucurbitadienol
Catalog No: CFN92378

Cucurbitadienol has significant anti-inflammatory, anti-tumor effect, is also CucurbitacinBE compounds biosynthesis the key intermediate. Cucurbitadienol synthase, the first committed enzyme for cucurbitacin biosynthesis, is a distinct enzyme from cycloartenol synthase for phytosterol biosynthesis. CYP87D18 catalyzed the oxidation of cucurbitadienol at C-11 to produce 11-oxo cucurbitadienol and 11-hydroxy cucurbitadienol.

Cudraflavanone B
Catalog No: CFN92532

Standard reference

Cudraflavone B
Catalog No: CFN91905

Cudraflavone B has anti-proliferative activity, mouse brain monoamine oxidase (MAO) inhibitory effects, apoptotic actions in human gastric carcinoma cells and mouse melanoma cells, and hepatoprotective activity. It may be a lead for the development of a potential candidate for human oral squamous cell carcinoma cells.

Cudratricusxanthone A
Catalog No: CFN89371

Cudratricusxanthone A has potent anti-proliferative, antioxidative, and monoamine oxidase inhibitory effects, it also possesses anti-cancer activities and provide a basis for developing effective therapeutic agents to inhibit growth and metastasis of breast cancer. Cudratricusxanthone A inhibits lipopolysaccharide-induced neuroinflammation through inhibition of NF-κB and p38 MAPK pathways in BV2 microglia. Cudratricusxanthone A has antiplatelet, anticoagulant, and profibrinolytic activities, it reversibly inhibits CYP1A2, 2C8, and 2C9. It also exhibits the significant hepatoprotective effect on nitrofurantoin-induced cytotoxicity in human liver-derived Hep G2 cells.